Study suggests convalescent plasma is more effective than monoclonal antibodies

We now have many drugs to help protect the most vulnerable from becoming seriously ill from COVID.

However, new variants have limited the effectiveness of one group -- monoclonal antibodies. A newly published paper shows the antibodies in convalescent plasma may be a better solution.

Convalescent plasma is taken from the blood of recently infected and fully recovered COVID-19 patients. In many cases, the plasma contains high levels of antibodies against the SARS-CoV-2 virus.

But unlike lab-produced monoclonal antibodies, the antibodies in convalescent plasma can attack a whole host of different proteins on the coronavirus -- making them helpful in preventing hospitalizations.

Watch the video above for the full report.

Read: More Good Health coverage